Earnings Feed
Start Free
Home/Filings/4/0000950170-24-095675
4//SEC Filing

Versant Ventures IV, LLC 4

Accession 0000950170-24-095675

CIK 0001544227other
View on SEC.govCompany Profile

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 8:33 PM ET

Size

25.5 KB

Accession

0000950170-24-095675

Insider Transaction Report

Form 4
Period: 2024-08-08
Tempest Therapeutics, Inc.TPST
Versant Vantage II GP, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Vantage II GP-GP, LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Venture Capital VI, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Ventures VI GP, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Venture Capital IV, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Side Fund IV, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644

  • Common Stock

    (indirect: See Footnote)
    1,171,094
Versant Ventures IV, LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Ventures VI GP-GP, LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Vantage II, L.P.
10% Owner
Transactions
  • Sale

    Common Stock

    2024-08-08$1.35/sh−400,000$540,040→ 597,940 total
  • Sale

    Common Stock

    2024-08-12$1.10/sh−387,999$426,993→ 209,941 total
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Footnotes (6)
  • [F1]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  • [F2]These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
  • [F3]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
  • [F4]These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV and may be deemed to share voting, investment and dispositive power over the shares held by VVC IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
  • [F5]These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV and may be deemed to share voting, investment and dispositive power over the shares held by VSF IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
  • [F6]These shares are held of record by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP and each may be deemed to share voting, investment and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP and Vantage II GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

Documents

1 file

Issuer

Tempest Therapeutics, Inc.

CIK 0001544227

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001456589

Filing Metadata

Form type
4
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 8:33 PM ET
Size
25.5 KB
View on SEC.gov